Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 160 matching trials from the live ClinicalTrials.gov search.
Conditions
Fibroid, Leiomyoma
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prescription of Letrozole for Uterine Myoma

NCT06143631
Conditions
Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
Interventions
Letrozole 2.5mg, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 53 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
Terminated Not applicable Interventional Results available

Uterine Filling Pressure in Hysteroscopy

NCT04550429
Conditions
Fibroids
Interventions
MyoSure Hysteroscopic Morcellator Device
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Fibroid Uterus
Interventions
Robot-assisted Laparoscopic myomectomy
Procedure
Lead sponsor
Ascher-Walsh, Charles, M.D.
Individual
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanistic Characterization of Uterine Pain

NCT04145518
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Completed Not applicable Interventional Results available

Symphion® System In-Office Study

NCT02520414
Conditions
Uterine Leiomyomas, Endometrial Polyps
Interventions
Symphion® Bipolar Hysteroscopic Tissue Resection System
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Canyon Country, California • Encinitas, California • Huntington Park, California + 35 more
Conditions
Uterine Fibroid
Interventions
Bearing nsPVA
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Uterine Fibroids, Infertility
Interventions
surgery utilizing V-Loc suture
Device
Lead sponsor
The Advanced Gynecologic Surgery Institute
Other
Eligibility
18 Years to 42 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Naperville, Illinois
Conditions
Menorrhagia, Uterine Fibroids
Interventions
Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Conditions
Uterine Fibroid
Interventions
Uterine Fibroid Option Grid encounter patient decision aid (text only), Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures), Uterine Fibroid Option Grid encounter patient decision aid (online)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

NCT03411980
Conditions
Uterine Fibroids, Endometriosis
Interventions
Vilaprisan (BAY1002670)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
Uterine Leiomyoma, Fibroids
Interventions
Pirfenidone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
35 Years to 50 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Uterine Fibroid
Interventions
Perfluten
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

NCT01069120
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
4
States / cities
Boynton Beach, Florida • Tampa, Florida • Houston, Texas
Active, not recruiting No phase listed Observational

Ascertaining Longterm Outcomes of Fibroid Treatments

NCT06430320
Conditions
Uterine Fibroid
Interventions
NA- no intervention
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
San Francisco, California • Detroit, Michigan • Rochester, Minnesota + 1 more
Conditions
Uterine Fibroids (UF)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Arlington, Virginia
Conditions
Fibroid
Interventions
PRA-027
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy

NCT04434066
Conditions
Abnormal Uterine Bleeding, Uterine Bleeding, Fibroid Uterus, Surgery
Interventions
Total Laparoscopic Hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Fibroids
Interventions
abdominal morcellation, vaginal morcellation
Procedure
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Uterine Fibroids
Interventions
Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • Sandy Springs, Georgia + 4 more
Conditions
Hysterectomy
Interventions
Peritoneal washings
Diagnostic Test
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Completed Not applicable Interventional Results available

Safety Study of ExAblate for the Treatment of Uterine Fibroids

NCT01142791
Conditions
Uterine Fibroids
Interventions
ExAblate
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more